A critical analysis of the MAESTRO-NASH trial's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for resmetirom in MASH.
A deep-dive into MAESTRO-NASH follow-up and extension data for resmetirom, covering durability of histological response, emergent safety signals, and what long-term outcomes look like beyond the original 52-week results.
A deep-dive into the MAESTRO-NASH phase 3 trial of resmetirom (Rezdiffra) for MASH with liver fibrosis, covering methodology, histological endpoints, safety data, and clinical implications.
A detailed breakdown of the MAESTRO-NASH trial results for resmetirom in MASH, covering primary and secondary endpoints, effect sizes, confidence intervals, subgroup analyses, and response distribution.
How the OASIS-1 trial of oral semaglutide 50 mg reshapes obesity treatment guidelines, prescribing patterns, and patient selection beyond the abstract results.
Deep dive into OASIS-1 trial follow-up and extension data for oral semaglutide 50 mg, covering weight regain patterns, durability of effect, and long-term safety signals beyond 68 weeks.
A detailed breakdown of the OASIS-1 trial design, randomization, estimand framework, and statistical choices that produced the 15.1% weight-loss result for oral semaglutide 50 mg.
A deep-dive overview of the OASIS-1 trial, the first randomized controlled trial testing oral semaglutide 50 mg for weight loss, reporting 15.1% body weight reduction at 68 weeks.
A deep-dive into the ODYSSEY OUTCOMES trial examining how alirocumab's 15% MACE reduction in post-ACS patients on high-intensity statins reshaped guidelines, prescribing patterns, and real-world cardiology decision-making.
A deep-dive into the enrollment biases, statistical caveats, generalizability gaps, and conflict-of-interest concerns surrounding the ODYSSEY OUTCOMES trial of alirocumab post-ACS.
Deep-dive into long-term follow-up from the ODYSSEY OUTCOMES trial of alirocumab post-ACS, covering durability of MACE reduction, safety signals beyond the primary analysis, and what clinicians should know about sustained PCSK9 inhibition.
A detailed breakdown of the ODYSSEY OUTCOMES trial design, randomization, blinding, endpoint adjudication, and statistical framework that produced the 15% MACE reduction for alirocumab after acute coronary syndrome.
A deep-dive overview of the ODYSSEY OUTCOMES trial, explaining how alirocumab reduced major cardiovascular events in patients after acute coronary syndrome already on high-intensity statins.
A deep-dive into the ODYSSEY OUTCOMES trial results for alirocumab post-ACS, covering primary and secondary endpoints, effect sizes, confidence intervals, time-course patterns, and subgroup analyses.
Deep-dive into pre-specified and post-hoc subgroup analyses from the ODYSSEY OUTCOMES trial of alirocumab post-ACS, examining differential MACE reduction by age, sex, BMI, baseline LDL-C, diabetes status, and more.
How the Olsen 2002 five-year finasteride trial reshaped prescribing for androgenetic alopecia, which guidelines it influenced, and what it means for patients outside the original study population.
A detailed breakdown of the enrollment biases, attrition problems, generalizability gaps, statistical caveats, and conflict-of-interest concerns in the landmark Olsen finasteride 5-year hair-loss study.
Deep-dive into the Olsen 2002 finasteride 5-year extension study: durability of hair count gains, regression patterns after discontinuation, long-term safety signals, and clinical implications for AGA treatment planning.
A detailed methodology breakdown of the Olsen et al. 2002 finasteride 1 mg trial, examining randomization design, endpoint definitions, statistical approach, and how each choice shapes interpretation of 5-year AGA hair count data.
A deep-dive into the landmark 5-year finasteride 1 mg trial for androgenetic alopecia, covering methodology, results, limitations, and clinical relevance.
A deep dive into the primary and secondary endpoint results from the Olsen et al. 5-year finasteride 1 mg trial for androgenetic alopecia, including hair count trajectories, response distributions, and vertex vs frontal data.
A review of the pre-specified and post-hoc subgroup analyses from the Olsen et al. 5-year finasteride 1 mg trial, examining response patterns by age, vertex vs frontal location, baseline hair count, and other clinical variables, with an honest accounting of which specific effect sizes require verification against the primary publication.
How the ORIGIN trial's neutral cardiovascular findings for insulin glargine reshaped guidelines, prescribing behavior, and risk conversations for early dysglycemia management.
Health-economic analyses from the ORIGIN trial examining cost per QALY of insulin glargine vs standard care in early dysglycemia, payer implications, and value calculations for patients.
Deep dive into the ORIGIN trial follow-up: long-term outcomes after insulin glargine vs standard care in early dysglycemia, durability of glycemic effects, and cardiovascular safety signals over extended observation.
A detailed breakdown of the ORIGIN trial's randomization, blinding, endpoint adjudication, comparator rationale, and statistical framework, and why each design choice matters for interpreting cardiovascular safety of insulin glargine in early dysglycemia.
A plain-English deep dive into the ORIGIN trial, which tested whether early insulin glargine could prevent cardiovascular events in people with dysglycemia. Full methodology, results, and clinical implications.
A deep-dive into the methodological gaps, enrollment biases, statistical caveats, and generalizability concerns in the PIONEER-1 trial of oral semaglutide for type 2 diabetes.
A deep-dive into the health-economic modeling, cost-per-QALY estimates, and payer-coverage realities surrounding oral semaglutide as studied in the PIONEER-1 trial.
A clinical-research deep dive into the PIONEER-1 trial design, estimand framework, blinding strategy, and statistical choices that shaped oral semaglutide's key A1C results in type 2 diabetes.
A deep dive into the PIONEER-1 trial's primary and secondary endpoint results for oral semaglutide in type 2 diabetes, including effect sizes, confidence intervals, time-course data, and response distribution.
Deep-dive into PIONEER-1 pre-specified and post-hoc subgroup analyses for oral semaglutide 14 mg in type 2 diabetes, examining response variation by age, sex, BMI, baseline A1C, race, and renal function.
A deep-dive into the methodological limitations, enrollment biases, and generalizability gaps of the PIONEER-6 cardiovascular outcomes trial for oral semaglutide in type 2 diabetes.
Deep dive into PIONEER-6 follow-up data on oral semaglutide cardiovascular safety in type 2 diabetes, including durability of MACE outcomes, emerging safety signals, and long-term lessons beyond the original 15.9-month median exposure.
A deep-dive into the PIONEER-6 cardiovascular outcomes trial for oral semaglutide in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
A deep-dive overview of the PIVENS trial (2010), the landmark RCT that tested vitamin E and pioglitazone against placebo for nonalcoholic steatohepatitis in adults without diabetes.
Detailed breakdown of PIVENS trial subgroup analyses for vitamin E and pioglitazone in NASH, examining responses by age, sex, BMI, baseline ALT, NAS score, and fibrosis stage.
Deep dive into the RECONNECT open-label extension for bremelanotide (Vyleesi) in HSDD: durability of effect, dropout patterns, long-term safety signals, and what 12+ months of data reveal beyond the key 24-week RCT.
Deep-dive into cost-effectiveness analyses from the REDUCE-IT trial of icosapent ethyl (Vascepa), including cost per QALY, payer coverage, list vs net pricing, and value for individual patients.
Deep dive into REDUCE-IT follow-up analyses, durability of icosapent ethyl's cardiovascular benefit, post-trial safety signals, and what long-term data reveal beyond the original 4.9-year median.
A deep-dive into REDUCE-IT's randomization, blinding, mineral oil placebo debate, endpoint adjudication, and statistical hierarchy, explaining how each design choice shapes interpretation of icosapent ethyl's 25% MACE reduction.
Complete breakdown of the REDUCE-IT trial results for icosapent ethyl, including primary and secondary MACE endpoints, hazard ratios with confidence intervals, Kaplan-Meier time-course data, and prespecified subgroup analyses.
Deep-dive into REDUCE-IT pre-specified and post-hoc subgroup analyses for icosapent ethyl (Vascepa), examining differential MACE reduction by age, sex, BMI, baseline triglycerides, race, and other clinical variables.
A deep dive into the REWIND trial's 12% MACE reduction with dulaglutide and what it means for real-world prescribing in type 2 diabetes, including guideline updates, patient selection, and primary prevention implications.
A critical analysis of the REWIND cardiovascular outcomes trial for dulaglutide, covering enrollment biases, generalizability gaps, statistical nuances, and post-publication commentary.
A plain-English deep dive into the REWIND cardiovascular outcomes trial for dulaglutide (Trulicity) in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
REWIND trial results: dulaglutide cut three-point MACE by 12% (HR 0.88, 95% CI 0.79-0.99) over 5.4 years in 9,901 patients, per the 2019 Lancet publication.
A deep-dive into the SCALE Obesity trial of liraglutide 3.0 mg, examining how its results reshaped weight-management guidelines, prescribing patterns, and real-world patient selection.
A deep dive into the SCALE Obesity trial's randomization, blinding, inclusion criteria, statistical framework, and comparator design for liraglutide 3.0 mg in chronic weight management.
A deep-dive into the SCALE Obesity and Prediabetes RCT (2015), explaining how liraglutide 3.0 mg demonstrated meaningful weight loss versus placebo over 56 weeks and what it means for clinical practice.
How the SELECT trial's 20% MACE reduction with semaglutide 2.4 mg reshapes prescribing for patients with obesity and established cardiovascular disease, even without diabetes.
What the SELECT trial's follow-up and extension analyses reveal about the durability of semaglutide 2.4 mg's cardiovascular benefits, long-term safety signals, and unanswered questions beyond the primary endpoint.
A plain-English deep dive into the SELECT trial, the landmark RCT that proved semaglutide 2.4 mg reduces heart attacks and strokes in people with obesity and existing cardiovascular disease, even without diabetes.
A deep-dive into the SELECT trial's primary and secondary endpoint results for semaglutide 2.4 mg, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of cardiovascular benefit.
Deep dive into the SELECT trial's pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg, examining differential MACE reduction by age, sex, BMI, race, and baseline biomarkers in patients with overweight/obesity and established cardiovascular disease.
A critical appraisal of the 2018 Sinclair low-dose oral minoxidil study for androgenetic alopecia, covering enrollment biases, follow-up gaps, statistical weaknesses, and generalizability concerns.
Deep-dive into the TRAVERSE bone fracture substudy's long-term follow-up findings, the 43% fracture increase signal with testosterone, durability of harm, and post-trial implications for TRT prescribing in older men.
A deep methodological analysis of the TRAVERSE Bone Fracture Substudy showing 43% increased fracture risk with testosterone in older hypogonadal men, examining randomization, blinding, endpoint adjudication, statistical frameworks, and what these design choices mean for clinical interpretation.
Deep-dive into the TRAVERSE bone fracture substudy results showing a 43% increase in fractures with testosterone replacement therapy in older men, including effect sizes, confidence intervals, subgroup analyses, and time-course patterns.
Detailed breakdown of pre-specified and post-hoc subgroup analyses from the TRAVERSE Bone Fracture Substudy, examining which older hypogonadal men faced the greatest fracture risk increase with testosterone replacement therapy.